A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease
← catalyst calendarNCT07717346 · readout ≤ 102 d
Sponsored by Krystal Biotech, Inc. (industry) · KRYS — their whole pipeline →.
Phase
Early Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
7estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-06 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hailey Hailey Disease
- Skin Diseases
- Lesion Skin
Intervention
- Biological: KB111
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of KB111
measured 12 weeks
Permalink · KRYS's whole pipeline · Catalyst calendar · Every registered study · What changed